Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy.
Zhou Q, Chen M, Wu G, Chang JH, Jiang O, Cui JW, Han G, Lin Q, Fang J, Chen GY, Wu YL. Zhou Q, et al. Among authors: cui jw. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. doi: 10.21037/tlcr-20-608. Transl Lung Cancer Res. 2020. PMID: 33209620 Free PMC article.
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.
Wu YL, Wang CL, Sun Y, Liao ML, Guan ZZ, Yang ZM, Zhou QH, Lu S, Cheng Y, Liu XQ, Zhang XC, Zhou C, Wang J, Zhou Q, Song Y, Han BH, Ma ZY, Yang F, Wang Q, Chuai SK, Shao Y, He W, Zhu G, Xiong L, Wang JJ, Chen KN, Zhang L, Mao WM, Ma SL, Feng JF, Yang XN, Xu L, Chen G, Zhao J, Song QB, Shen-Tu Y, Qiao GB, Yu D, Yu SY, Hu Y, Chen M, Chen GY, Fan Y, Zhang HL, Liang J, Zhu GY, Cui JW, Yang JJ, Zhao Q, Zhao MF, Lu Y, Chang JH, Li JL, Yang Y, Hu J, Gu CD, Zhang YC, Zhong WZ. Wu YL, et al. Among authors: cui jw. ESMO Open. 2017 Apr 4;2(Suppl 1):e000174. doi: 10.1136/esmoopen-2017-000174. eCollection 2017. ESMO Open. 2017. PMID: 28848676 Free PMC article. Review.
Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304).
Song Y, Wu YL, Cao LJ, Chen JH, Ma ZY, Cui JW, Wang J, Liu HB, Ding JY, Hu M. Song Y, et al. Among authors: cui jw. Am J Clin Oncol. 2019 May;42(5):432-439. doi: 10.1097/COC.0000000000000538. Am J Clin Oncol. 2019. PMID: 30950859 Free PMC article. Clinical Trial.
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer.
Yang Y, Wu B, Huang L, Shi M, Liu Y, Zhao Y, Wang L, Lu S, Chen G, Li B, Xie C, Fang J, Yang N, Zhang Y, Cui J, Song Y, Zhang C, Mei X, Cao B, Yang L, Cheng Y, Ying K, Sun T, Ren B, Yu Q, Liao Z, Pei Z, Wang M, Zhou J, Yu S, Feng G, Wan H, Wang H, Gao S, Wang J, An G, Geng Y, Ji Y, Yuan Y, Ma S, Jia Z, Hu M, Zhou H, Yu J, Sun X, Zhang L. Yang Y, et al. Transl Lung Cancer Res. 2019 Dec;8(6):989-999. doi: 10.21037/tlcr.2019.12.23. Transl Lung Cancer Res. 2019. PMID: 32010577 Free PMC article.
The patient-generated subjective global assessment is a promising screening tool for cancer cachexia.
Cong M, Song C, Xu H, Song C, Wang C, Fu Z, Ba Y, Wu J, Xie C, Chen G, Chen Z, Zhou L, Li T, Deng L, Xin L, Yang L, Cui J, Shi H; Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) Group. Cong M, et al. BMJ Support Palliat Care. 2022 May;12(e1):e39-e46. doi: 10.1136/bmjspcare-2020-002296. Epub 2020 Aug 21. BMJ Support Palliat Care. 2022. PMID: 32826265
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma.
Guo LH, Zhang MF, Zhang HL, Zhou JY, Cai XH, Long Y, Guo QS, Yang N, Zhao J, Xie ZH, Jiang B, Zhu Y, Fan Y, Xie CY, Hu Y, Yao Y, Jia J, Li XL, Cui JW, Sui XZ, Lin W, Cheng Y, Wang HJ, Wang CL, Zhao MF, Qiao GB, Peng LJ, Yang L, Chen GY, Cai KC, Xu XH, Zhang LM, Feng GS, Zhou JM, Wu GW, Dong XR, Wang LF, Zhang HM, Gao YJ, Jiang QY, Cang SD, Yang ZX, Song X, Liu XQ, Zhu B, Chen FX, Hu CH, Chen X, Wu YL, Zhou Q. Guo LH, et al. Among authors: cui jw. Front Oncol. 2020 Sep 15;10:1568. doi: 10.3389/fonc.2020.01568. eCollection 2020. Front Oncol. 2020. PMID: 33042801 Free PMC article.
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J; CameL Study Group. Zhou C, et al. Lancet Respir Med. 2021 Mar;9(3):305-314. doi: 10.1016/S2213-2600(20)30365-9. Epub 2020 Dec 18. Lancet Respir Med. 2021. PMID: 33347829 Clinical Trial.
358 results